Can Natural Killer Cell Activity Help Screen Patients Requiring a Biopsy for the Diagnosis of Prostate Cancer?

Overview

Journal Int Braz J Urol

Specialty Urology

Date 2020 Feb 6

PMID 32022514

Citations 3

Authors

Bum Sik Tae

Byeong Jo Jeon

Young Hoon Lee

Hoon Choi

Jae Young Park

Jae Hyun Bae

Affiliations

Soon will be listed here.

Abstract

Purpose: To evaluate the usefulness of natural killer cell activity (NKA) in diagnosing prostate cancer (PC).

Materials And Methods: The medical records of patients who underwent transrectal prostate biopsy (TRBx) at Korea University Ansan Hospital between May 2017 and December 2017 were retrospectively reviewed. NKA levels were measured using NK VueR Tubes (ATgen, Sungnam, Korea). All blood samples were obtained at 8 AM on the day of biopsy. Patients with other malignancies, chronic inflammatory conditions, high prostate-specifi c antigen (PSA) level (>20ng/mL), or history of taking 5-alphareductase inhibitor or testosterone replacement therapy were excluded.

Results: A total of 102 patients who underwent TRBx for PC diagnosis were enrolled. Among them, 50 were diagnosed with PC. Significant differences in age and NKA level were observed between the PC and no-PC groups. Receiver operating characteristic (ROC) curve analysis showed that the optimal cut-off of NKA level for the prediction of PC was 500pg/dL, with a sensitivity of 68.0% and a specifi city of 73.1%. In addition, NKA level (0.630) had the greatest area under the ROC curve compared to those for the ratio of total PSA to free PSA (0.597) and PSA density (0.578).

Conclusions: The results of this pilot study revealed that low NKA and high PSA levels were likely to be associated with a positive TRBx outcome. NKA detection was easy and improved the diagnostic accuracy of PC.

Citing Articles

NK Cell-Microbiota Interaction Biomarker Strategy: Advancing Prostate Cancer Management.

Fanijavadi S, Hansen T, Zedan A Biomolecules. 2025; 15(2).

PMID: 40001576 PMC: 11852595. DOI: 10.3390/biom15020273.

Natural killer cell activity in metastatic castration resistant prostate cancer patients treated with enzalutamide.

Zedan A, Nederby L, Volmer L, Madsen C, Sorensen B, Hansen T Sci Rep. 2023; 13(1):17144.

PMID: 37816781 PMC: 10564750. DOI: 10.1038/s41598-023-43937-7.

Harnessing Natural Killer Cell Function for Genitourinary Cancers.

Bhardwaj N, Farkas A, Gul Z, Sfakianos J Urol Clin North Am. 2020; 47(4):433-442.

PMID: 33008494 PMC: 7992041. DOI: 10.1016/j.ucl.2020.07.002.

Bladder Cancer highlighted.

Favorito L Int Braz J Urol. 2020; 46(2):150-151.

PMID: 32022505 PMC: 7025828. DOI: 10.1590/S1677-5538.IBJU.2020.02.01.

References

Wolf A, Wender R, Etzioni R, Thompson I, DAmico A, Volk R . American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin. 2010; 60(2):70-98. DOI: 10.3322/caac.20066. View

Pasero C, Gravis G, Guerin M, Granjeaud S, Thomassin-Piana J, Rocchi P . Inherent and Tumor-Driven Immune Tolerance in the Prostate Microenvironment Impairs Natural Killer Cell Antitumor Activity. Cancer Res. 2016; 76(8):2153-65. DOI: 10.1158/0008-5472.CAN-15-1965. View

Skarmoutsos A, Skarmoutsos I, Katafigiotis I, Tataki E, Giagini A, Alamanis C . Detecting Novel Urine Biomarkers for the Early Diagnosis of Prostate Cancer: Platelet Derived Growth Factor-BB as a Possible New Target. Curr Urol. 2018; 12(1):13-19. PMC: 6198783. DOI: 10.1159/000447225. View

Tarle M, Kraljic I, Kastelan M . Comparison between NK cell activity and prostate cancer stage and grade in untreated patients: correlation with tumor markers and hormonal serotest data. Urol Res. 1993; 21(1):17-21. DOI: 10.1007/BF00295186. View

Esfahani M, Ataei N, Panjehpour M . Biomarkers for evaluation of prostate cancer prognosis. Asian Pac J Cancer Prev. 2015; 16(7):2601-11. DOI: 10.7314/apjcp.2015.16.7.2601. View

Kastelan M, Kraljic I, Tarle M . NK cell activity in treated prostate cancer patients as a probe for circulating tumor cells: hormone regulatory effects in vivo. Prostate. 1992; 21(2):111-20. DOI: 10.1002/pros.2990210204. View

Etheridge T, Straus J, Ritter M, Jarrard D, Huang W . Semen AMACR protein as a novel method for detecting prostate cancer. Urol Oncol. 2018; 36(12):532.e1-532.e7. DOI: 10.1016/j.urolonc.2018.09.010. View

Verma A, St Onge J, Dhillon K, Chorneyko A . PSA density improves prediction of prostate cancer. Can J Urol. 2014; 21(3):7312-21. View

Ljunggren H, Malmberg K . Prospects for the use of NK cells in immunotherapy of human cancer. Nat Rev Immunol. 2007; 7(5):329-39. DOI: 10.1038/nri2073. View

10.

Song W, Choo S, Sung H, Han D, Jeong B, Seo S . Incidence and management of extended-spectrum beta-lactamase and quinolone-resistant Escherichia coli infections after prostate biopsy. Urology. 2014; 84(5):1001-7. DOI: 10.1016/j.urology.2014.06.052. View

11.

Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch M, De Santis M . EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2016; 71(4):618-629. DOI: 10.1016/j.eururo.2016.08.003. View

12.

Cary K, Cooperberg M . Biomarkers in prostate cancer surveillance and screening: past, present, and future. Ther Adv Urol. 2013; 5(6):318-29. PMC: 3825107. DOI: 10.1177/1756287213495915. View

13.

Loeb S, Bjurlin M, Nicholson J, Tammela T, Penson D, Carter H . Overdiagnosis and overtreatment of prostate cancer. Eur Urol. 2014; 65(6):1046-55. PMC: 4113338. DOI: 10.1016/j.eururo.2013.12.062. View

14.

Jung K, Won Y, Oh C, Kong H, Cho H, Lee J . Prediction of Cancer Incidence and Mortality in Korea, 2016. Cancer Res Treat. 2016; 48(2):451-7. PMC: 4843733. DOI: 10.4143/crt.2016.092. View

15.

Bryceson Y, Chiang S, Darmanin S, Fauriat C, Schlums H, Theorell J . Molecular mechanisms of natural killer cell activation. J Innate Immun. 2011; 3(3):216-26. DOI: 10.1159/000325265. View

16.

Hou H, Mao L, Wang J, Liu W, Lu Y, Yu J . Establishing the reference intervals of NK cell functions in healthy adults. Hum Immunol. 2016; 77(8):637-642. DOI: 10.1016/j.humimm.2016.05.022. View

17.

Pasero C, Gravis G, Granjeaud S, Guerin M, Thomassin-Piana J, Rocchi P . Highly effective NK cells are associated with good prognosis in patients with metastatic prostate cancer. Oncotarget. 2015; 6(16):14360-73. PMC: 4546472. DOI: 10.18632/oncotarget.3965. View

18.

Kallal L, Biron C . Changing partners at the dance: Variations in STAT concentrations for shaping cytokine function and immune responses to viral infections. JAKSTAT. 2013; 2(1):e23504. PMC: 3670271. DOI: 10.4161/jkst.23504. View

19.

Delahanty D, Wang T, Maravich C, Forlenza M, Baum A . Time-of-day effects on response of natural killer cells to acute stress in men and women. Health Psychol. 2000; 19(1):39-45. DOI: 10.1037//0278-6133.19.1.39. View

20.

Lin S, Chou F, Li L, Lin C, Yeh S, Chang C . Natural killer cells suppress enzalutamide resistance and cell invasion in the castration resistant prostate cancer via targeting the androgen receptor splicing variant 7 (ARv7). Cancer Lett. 2017; 398:62-69. DOI: 10.1016/j.canlet.2017.03.035. View